Oxymetazoline: Research History & Formulation Comparisons

How the research connects to the formula

The listed formula contains oxymetazoline 0.88%, ivermectin 0.88% and niacinamide 4%. The ingredient map preserves those numbers while connecting each component to its own research.

A rosacea study may measure persistent redness, lesions, or a participant’s assessment. These outcomes should remain separate when the two active ingredients are discussed in the same cream.

Current HealthRX.com formulation map
Product	Listed formulation	Connected ingredient research
Rosacea Cream (Oxymetazoline + Ivermectin)	Oxymetazoline 0.88% / Ivermectin 0.88% / Niacinamide 4%	Oxymetazoline · Ivermectin · Niacinamide

Publication history

When the ingredient appeared in the literature

The chart counts records mentioning the search terms in their title or abstract. It includes research beyond skin. Use the period controls to inspect the count.

2026: 26 indexed publications. 2026 includes publications dated through October 5. The earlier bars cover longer periods than the annual bars.

View the chart as a data table

Period	Publications
1900-1959	0
1960-1969	9
1970-1979	50
1980-1989	165
1990-1999	340
2000-2009	154
2010-2014	66
2015-2019	91
2020	22
2021	24
2022	23
2023	17
2024	17
2025	35
2026	26

Search query and data source

Source: Europe PMC’s PubMed-indexed records. Retrieved October 5, 2026. The index’s firstPublicationDate field supplies the dates and chart periods; it can normalize a month-only record to the first day of the month. Dates through October 5 are included. Counts can change as the index adds or corrects records.

TITLE_ABS:(oxymetazoline) AND SRC:MED AND FIRST_PDATE:[1900-01-01 TO 2026-10-05]

Open this literature search · Download the data

A closer search for this product question

The focused search returns 49 publications. It narrows the ingredient query to terms connected with its catalog use. Its displayed records remain a search sample, not a ranking of study quality.

View the focused query

TITLE_ABS:(oxymetazoline) AND TITLE_ABS:(rosacea) AND SRC:MED AND FIRST_PDATE:[1900-01-01 TO 2026-10-05]

Open the focused search

Dated publications

Read individual records in context

The timeline combines selected references with a sample from the ingredient search. Dates use the index’s firstPublicationDate field; the PubMed record may distinguish an earlier online date from the print date. Written study notes appear alongside the records that have them. Other entries show the indexed bibliography and link to the paper.

Clinical Trial, Phase II · research-article · Journal Article

Efficacy and Safety of Oxymetazoline 1% Cream for the Treatment of Mild to Moderate Facial Rosacea.

Sajdeh F, Samadi A, Naeimifar A, Yazdanparast T, Ahmadi M, Amiri F, Kassir M, Firooz A, Nasrollahi SA. Journal of cosmetic dermatology. PMID 40165547.

This record identifies a publication and its indexed publication types. The full paper contains the study methods, population, formulation and results.

Read the PubMed record · Publisher record

Questions that shape the comparison

Does the paper study a topical facial preparation? Is its primary outcome redness, lesion count or another measure?

Source records

Efficacy and Safety of Oxymetazoline 1% Cream for the Treatment of Mild to Moderate Facial Rosacea.Sajdeh F, Samadi A, Naeimifar A, Yazdanparast T, Ahmadi M, Amiri F, Kassir M, Firooz A, Nasrollahi SA.Journal of cosmetic dermatology. 2025-04-01. PMID 40165547. Clinical Trial, Phase II, research-article, Journal Article.

Efficacy of Widely Used Topical Drugs for Rosacea: A Systematic Review and Meta-Analysis.Gao X, Xiang W.Actas dermo-sifiliograficas. 2025-04-15. PMID 40246142. Meta-Analysis, Systematic Review, Journal Article.

Efficacy of Pseudoephedrine and Oxymetazoline in Preventing Otic Barotrauma: A Systematic Review and Meta-Analysis.AlGhamdi MA, Katib RI, Bawazir RO, Alanazi NF, Kouther DA, AlDajani N.Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2026-04-03. PMID 41931637. Meta-Analysis, Systematic Review, Journal Article.

Rebound hypertension following prolonged oxymetazoline use: a signal-generating case report.Merante D.Therapeutic advances in drug safety. 2026-04-06. PMID 41952952. Journal Article, Case Reports, case-report.

The Latest Advances in Rosacea Treatment: A Systematic Review.Andrusiewicz A, Khimuk S, Niżnik J, Sirko D, Mijas D, Nowicka D.Pharmaceuticals (Basel, Switzerland). 2026-06-24. PMID 42515667. review-article, Review, Journal Article.

Oxymetazoline Can Shorten the Time Required for a Bronchoscope to Reach the Vocal Cords in Patients With Turbinate Hypertrophy.Zhang J, Meng F.Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery. 2026-06-26. PMID 42359707. research-article, Randomized Controlled Trial, Journal Article.

Oxymetazoline hydrochloride nasal spray for nasal function recovery after endoscopic transsphenoidal pituitary adenectomy: a propensity score-matched cohort study.Yan L, Feng F, Wei Y, Zhang J, Chen C, Cai Y, Yang Y, Zhang M, Zhao Q.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2026-07-29. PMID 42520486. Journal Article.

Hemodynamic Effects of Topical Oxymetazoline During Pediatric Flexible Bronchoscopy.Katz AJ, Haskett H, Grant LMC, Corcoran A, Daou AW, Phinizy P, Bruins BB, Mazandi VM, Senthil K, Piccione J, Kelchtermans J.Journal of bronchology & interventional pulmonology. 2026-08-17. PMID 42605254. Journal Article.

Research data assembled by HealthRX.com from the displayed source records, October 5, 2026. The atlas contains a dated literature search and selected studies; it is not an exhaustive systematic review.